Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
about
New and emerging disease modifying therapies for multiple sclerosisOfatumumab: a novel monoclonal anti-CD20 antibodyRituximab: mechanism of actionOfatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataNew developments in the management of chronic lymphocytic leukemia: role of ofatumumabNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsMechanisms of action of therapeutic antibodies for cancerAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationInduced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Complement is activated by IgG hexamers assembled at the cell surface.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsAntigenic modulation and rituximab resistance.Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.Antibody Therapies in Cancer.Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsOfatumumab, a human anti-CD20 monoclonal antibody.Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Complement and HIV-I infection/HIV-associated neurocognitive disorders.Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.New insights of an old defense system: structure, function, and clinical relevance of the complement system.Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trialCancer immunotherapy comes of ageBuilding better monoclonal antibody-based therapeutics.A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.Therapeutic antibodies against cancer.Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer.Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.Rituximab mediates loss of CD19 on B cells in the absence of cell death.A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
P2860
Q22242305-CFB69306-F24A-47B0-809D-7F10D9A5F197Q24604065-07F71BE0-B848-4B71-8628-DE8BE30E2DEBQ24607358-8A44BBB3-E6F6-4AC4-B818-743038F6D818Q26738934-16429F47-FFC2-4388-A8AE-5763FA8884BEQ26768396-8B380CE3-E74C-4F6F-BA8A-AB02B65A5D02Q26782270-EB289B5B-FBC6-4170-8B2B-142F9352EC4FQ26783600-B69427DF-E4C8-48D5-ADD4-1BE8569A9AB0Q26849243-33331C12-920A-4248-B2DE-1A81A6334C5CQ28385366-0ADCC964-DBCD-4A20-8EBC-CDFDC9570D27Q30275229-54335870-C726-4406-B60B-25BA163E0470Q30276243-4C57AE8E-AEFA-4797-B6AC-CED96D287CEAQ30356145-1EE1EE7F-CE06-494F-A7CA-993E837677DAQ30360964-BAD20E23-A515-4C4B-AC1D-C76EF1375886Q30405847-966CC006-B710-4B69-89C6-19699DE1E502Q30409381-22C0468B-8AC1-44DF-921C-8CE062DC08FFQ30421637-378CD8E6-8625-4F14-92F4-EB8CEDE61AAAQ30432874-085C4813-EBB5-45E3-9CE6-4B63F1602417Q30453680-1807ED0A-1F7C-468C-AE52-B641176E0CE0Q31104000-4D4E9FCE-E682-4606-BAEF-D49B6A2C327BQ33394947-A2898459-3BB6-4285-93BD-67860252EF27Q33406478-801B9D11-3958-413B-96F0-EA019414832FQ33733443-C29B78D7-FA21-4DB1-A423-4E86A902E2BAQ34095311-6BEF4167-F828-456F-B6CE-BD9F1D472C36Q34194706-94C4472A-D265-4149-A1E9-2491CA1BA11BQ34610122-EB2BCE3A-229D-4D21-B259-38375B2066B5Q34617307-AB6C4066-8D74-4E58-8705-D695CEF837E1Q34623592-41694603-DC00-486A-AE40-8D44641C008CQ34699496-E6F5AA36-99A7-4C71-9DA5-29E2E5E018B8Q35506520-2DF72322-C2DF-4083-ADFE-8289D9C2B0E3Q35540009-398F1803-8F27-4358-9949-CE68572F5D83Q35666338-D2768348-2DCF-4253-A353-B43600A732B3Q35817552-FD32E94F-C8CD-453D-BAFF-87D34CE5F72CQ35886917-9606E2E4-E3EB-4BCC-98DC-98F52688A367Q35908498-78A4EB7A-5630-4FC6-82FE-CB5068327A58Q36060036-3D2A7830-1C06-4D44-80E7-C7730B844E46Q36152165-D8C35FB7-B4F5-4AA3-8A7F-139FA63D965CQ36173272-87F22F86-60E6-4EA1-A4A9-D3D2580CF247Q36213094-3E757CB9-4A8A-4012-BBED-B2192F44B7DBQ36252683-F1A5197D-6FA1-4982-A173-F01788805F75Q36759405-488200DF-3A87-4417-B216-8C686CBE7495
P2860
Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Binding of submaximal C1q prom ...... re induced by OFA than by RTX.
@ast
Binding of submaximal C1q prom ...... re induced by OFA than by RTX.
@en
type
label
Binding of submaximal C1q prom ...... re induced by OFA than by RTX.
@ast
Binding of submaximal C1q prom ...... re induced by OFA than by RTX.
@en
prefLabel
Binding of submaximal C1q prom ...... re induced by OFA than by RTX.
@ast
Binding of submaximal C1q prom ...... re induced by OFA than by RTX.
@en
P2093
P356
P1476
Binding of submaximal C1q prom ...... are induced by OFA than by RTX
@en
P2093
Andrew W Pawluczkowycz
Frank J Beurskens
Jan G J van de Winkel
Margaret A Lindorfer
Paul V Beum
Ronald P Taylor
P304
P356
10.4049/JIMMUNOL.0900632
P407
P577
2009-06-17T00:00:00Z